Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 5 mg | 2-3 weeks | $ 127 | |
| 10 mg | 2-3 weeks | $ 228 | |
| 20 mg | 2-3 weeks | $ 361 | |
| 50 mg | 2-3 weeks | $ 750 | |
| 100 mg | 2-3 weeks | $ 1177 |
| Description | Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM. |
| Targets&IC50 | JAK2: 6 nM, JAK1: 12 nM, Tyk2: 0.5 nM, JAK3: 8 nM, Syk: 32 nM |
| In vitro | Cell lines (Ramos RA-1, Daudi, Toledo, SU-DHL4 and SU-DHL6) are cultured in RPMI media supplemented with 10% fetal bovine serum. Cells are treated with the indicated concentrations of PRT062070, the SYK-selective inhibitor PRT060318, the pan-JAK inhibitor 1, a 1:1 combination of PRT060318 and JAK inhibitor 1, or vehicle control (0.5% dimethylsulfoxide) for 72 hours. Cell viability assays are performed using CellTiter Glo in 384-well plates. Cells are seeded at a density of 5000 cells per well. (Only for Reference) |
| Synonyms | PRT062070 hydrochloride, Cerdulatinib, PRT2070, PRT062070, PRT2070 hydrochloride |
| CAS No. | 1369761-01-2 |
| Chemical Formula | C20H28ClN7O3S |
| Molecular Weight | 482 |
| Solubility | Ethanol: <1 mg/mL H2O: <1 mg/mL; DMSO: 40 mg/mL (83 mM) |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
